Clinical trial · Interventional
Value of Macrophage-Colony Stimulating Factor as a New Marker of Bone Lesions in Multiple Myeloma
NCT02800954CI-TRIAL-00097502MCSF-MYELOMEcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The Primary objective of this study is to compare serum levels of Macrophage-Colony Stimulating Factor (M-CSF) in a population of patients with multiple myeloma (MM), in a population of patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and in a control population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood samples | Biological | — | UNRESOLVED |
| Bone marow samples | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- multiple myeloma group
- description
- case group = patients with multiple myeloma
- interventionNames
- Biological: blood samples
- Biological: Bone marow samples
- type
- EXPERIMENTAL
- label
- MGUS group
- description
- monoclonal gammopathy of undetermined significance
- interventionNames
- Biological: blood samples
- Biological: Bone marow samples
- type
- OTHER
- label
- healthy control group
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: For the multiple myeloma group * confirmed diagnosis of de novo multiple myeloma according to the International Myeloma Working Group criteria * bisphosphonate therapy for more than 60 days, * signature of the informed consent form, * patients over the age of 18 years. For the monoclonal gammopathy of undetermined significance (MGUS) group * confirmed diagnosis of MGUS according to the International Myeloma Working Group criteria * signature of the informed consent form, * patients over the age of 18 years. For the healthy control group * signature of the informed consent form, * subjects over the age of 18 years. Exclusion Criteria: * patients with thyroid or parathyroid disease, * osteomalacia, rheumatoid arthritis, Paget's disease, osteoporosis, * bisphosphonate therapy for less than 60 days, * absence of informed consent, * patients under the age of 18 years.
References
Publications (1)
- RESULTFrom the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO); Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, Eesa M, Fischer U, Hausegger K, Hirsch JA, Shazam Hussain M, Jansen O, Jayaraman MV, Khalessi AA, Kluck BW, Lavine S, Meyers PM, Ramee S, Rufenacht DA, Schirmer CM, Vorwerk D. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018 Aug;13(6):612-632. doi: 10.1177/1747493018778713. Epub 2018 May 22. No abstract available. PMID 29786478